Sabrina Figueroa

Master's

Biomedical Science

University of California

- Skaggs School of Pharmacy & Pharmaceutical Sciences - Investor Pitch Deck (from PoC to IND & Clinical Trials - Conducted a patent search and freedom to operate (FTO) analysis for novel metabolic disease therapies, focusing on - Structured a 10-year clinical trial plan transitioning from IND to NDA for a small molecule therapeutic and to a PMA for a complementary diagnostic, including risk mitigation strategies - Developed strategic and tactical plans for launching biopharmaceutical products in the precision medicine space - Prepared detailed financial forecasts, including balance sheets, cash flow projections, and capitalization tables to support - Drug Development & Product Management - Developed a Marketing and Pharmacoeconomics plan for an orphan disease drug's upcoming launch, covering prelaunch - Conducted market research for Fabry-Anderson Disease. Connected with over 60 patients over 1.5 months - Received personal recommendations from director MSR of Chiesi Farmaceutici LATAM at Biopas Laboratorios - Mexico, D.F. to develop a sensible market access plan for global marketing - Conducted cost-effectiveness analysis, budget impact analysis, and economic modeling including projections and sensitivity analyses using Microsoft Excel - Clinical Trial Design and Execution (P1-P3 - Developed a Target Product Profile (TPP) for a competitive anti-PCSK9 Antibody: improved binding affinity - Designed and implemented a pharmacokinetic (PK) modeling system for a novel drug using R, focusing on predictive - PK/PD relationships, and optimizing dosing regimens - Created a clinical development plan (CDP) covering phases 0-3 with a detailed timeline to meet strategic goals - Designed a Clinical Development Plan (P0-P3) with a timeline to reach target goals (KPI based - Implemented AI approaches to help the recruitment and patient inclusion/exclusion criteria for multi-site, closed-label - Conducted midpoint efficacy assessments using historical statistical data and R programming, positioning the drug as a